Literature DB >> 7907016

The somatostatin receptors SSTR1 and SSTR2 are coupled to inhibition of adenylyl cyclase in Chinese hamster ovary cells via pertussis toxin-sensitive pathways.

R E Hershberger1, B L Newman, T Florio, J Bunzow, O Civelli, X J Li, M Forte, P J Stork.   

Abstract

Somatostatin exerts multiple effects throughout the body by binding to specific somatostatin receptors. Two classes of somatostatin receptors, SRIF1 and SRIF2, have been distinguished biochemically and pharmacologically. Two cDNAs have been recently isolated that encode somatostatin receptors 1 and 2 (SSTR1 and SSTR2, respectively). The pharmacological characteristics of receptors expressing these cDNAs resemble those of the SRIF2 and SRIF1 classes of somatostatin receptors, respectively. We stably expressed the rat homologs of both receptors in Chinese hamster ovary (CHO) cells (type K1). These transfected cell lines recognized the endogenous ligands SS14 and SS28 with high affinity, whereas the synthetic analog MK678 identified only SSTR2. In preparations of CHO-SSTR1 or CHO-SSTR2 cells, SS14 and SS28 inhibited forskolin-stimulated adenylyl cyclase activity by approximately 35%, with ED50 values in the nanomolar range. The adenylyl cyclase inhibition was dependent upon the guanine nucleotide GTP and could be ablated with pertussis toxin preincubation. The present data indicate that SSTR1 and SSTR2 are coupled to inhibition of adenylyl cyclase via pertussis toxin- sensitive G-proteins.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7907016     DOI: 10.1210/endo.134.3.7907016

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  7 in total

Review 1.  Somatostatin.

Authors:  T Reisine
Journal:  Cell Mol Neurobiol       Date:  1995-12       Impact factor: 5.046

Review 2.  International Union of Basic and Clinical Pharmacology. CV. Somatostatin Receptors: Structure, Function, Ligands, and New Nomenclature.

Authors:  Thomas Günther; Giovanni Tulipano; Pascal Dournaud; Corinne Bousquet; Zsolt Csaba; Hans-Jürgen Kreienkamp; Amelie Lupp; Márta Korbonits; Justo P Castaño; Hans-Jürgen Wester; Michael Culler; Shlomo Melmed; Stefan Schulz
Journal:  Pharmacol Rev       Date:  2018-10       Impact factor: 25.468

Review 3.  Nanoparticle ligand presentation for targeting solid tumors.

Authors:  Jason T Duskey; Kevin G Rice
Journal:  AAPS PharmSciTech       Date:  2014-06-14       Impact factor: 3.246

4.  Somatostatin receptor-1 induces cell cycle arrest and inhibits tumor growth in pancreatic cancer.

Authors:  Min Li; Xiaochi Wang; Wei Li; Fei Li; Hui Yang; Hao Wang; F Charles Brunicardi; Changyi Chen; Qizhi Yao; William E Fisher
Journal:  Cancer Sci       Date:  2008-09-22       Impact factor: 6.716

5.  Somatostatin and leu-enkephalin in the rat auditory brainstem during fetal and postnatal development.

Authors:  M Kungel; E Friauf
Journal:  Anat Embryol (Berl)       Date:  1995-05

Review 6.  Biological and Biochemical Basis of the Differential Efficacy of First and Second Generation Somatostatin Receptor Ligands in Neuroendocrine Neoplasms.

Authors:  Federico Gatto; Federica Barbieri; Marica Arvigo; Stefano Thellung; Jessica Amarù; Manuela Albertelli; Diego Ferone; Tullio Florio
Journal:  Int J Mol Sci       Date:  2019-08-13       Impact factor: 5.923

7.  Peptide receptor targeting in cancer: the somatostatin paradigm.

Authors:  Federica Barbieri; Adriana Bajetto; Alessandra Pattarozzi; Monica Gatti; Roberto Würth; Stefano Thellung; Alessandro Corsaro; Valentina Villa; Mario Nizzari; Tullio Florio
Journal:  Int J Pept       Date:  2013-02-07
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.